PCSK9 and familial hyperaldosteronism: Similarly, in FH models, PCSK9 monoclonal antibodies exhibited neuroprotective effects by modulating the immune microenvironment, reducing neuroinflammation, and enhancing blood–brain barrier integrity [119].